

Table 8. NSW PHO performances in clinical trial authorisations (greater than low risk) during the reporting period, by sponsor type.

| | Collaborative group | | | Commercial entity | | | Investigator-initiated | | |
|--------------|-------------------------|-------------------------------------|---------------------------|-------------------------|-------------------------------------|---------------------------|-------------------------|-------------------------------------|---------------------------|
| NSW PHOs | Total # of Applications | Average Research Office Time (days) | Average Total Time (days) | Total # of Applications | Average Research Office Time (days) | Average Total Time (days) | Total # of Applications | Average Research Office Time (days) | Average Total Time (days) |
| ASNSW | 0 | - | - | 0 | - | - | 0 | - | - |
| CALVARY | 2 | 8 | 8 | 5 | 10 | 14 | 0 | - | - |
| CCLHD | 0 | - | - | 1 | 5 | 6 | 3 | 13 | 33 |
| FWLHD | 0 | - | - | 0 | - | - | 0 | - | - |
| HNELHD | 1 | 2 | 16 | 2 | 4 | 5 | 3 | 10 | 32 |
| ISLHD | 1 | 0 | 3 | 1 | 4 | 5 | 0 | - | - |
| JHFMHN | 0 | - | - | 0 | - | - | 0 | - | - |
| MLHD | 0 | - | - | 0 | - | - | 0 | - | - |
| MNCLHD | 3 | 22 | 38 | 1 | 13 | 21 | 2 | 0 | 33 |
| NBMLHD | 0 | - | - | 2 | 6 | 73 | 0 | - | - |
| NNSWLHD | 0 | - | - | 0 | - | - | 0 | - | - |
| NSLHD | 7 | 36 | 59 | 8 | 12 | 21 | 7 | 16 | 43 |
| NSWHPH | 0 | - | - | 0 | - | - | 0 | - | - |
| SCHN | 1 | 24 | 95 | 1 | 9 | 78 | 0 | - | - |
| SESLHD | 6 | 5 | 46 | 11 | 13 | 36 | 4 | 12 | 45 |
| SLHD-CCD | 2 | 28 | 37 | 9 | 10 | 32 | 0 | - | - |
| SLHD-RPA | 6 | 23 | 49 | 18 | 14 | 31 | 5 | 10 | 33 |
| SNSWLHD | 0 | - | - | 0 | - | - | 1 | 105 | 105 |
| SVHN | 2 | 8 | 19 | 6 | 11 | 46 | 5 | 12 | 69 |
| SWSLHD | 6 | 71 | 137 | 17 | 51 | 84 | 5 | 61 | 131 |
| WNSWLHD | 3 | 13 | 50 | 0 | - | - | 0 | - | - |
| WSLHD | 5 | 27 | 73 | 23 | 12 | 30 | 5 | 8 | 65 |
| Total | 48 | 28 | 63 | 105 | 20 | 42 | 40 | 20 | 60 |

OHMR Research Ethics and Governance Metrics Program



Metrics Activity Report for NSW PHOs

Reporting Period: Quarter 1 2024
01/01/2024 – 31/03/2024

NSW Office for Health and Medical Research

Executive Summary

This report includes strategic and site level performance and compliance metrics that are collected by the Office for Health and Medical Research (OHMR) from NSW Public Health Organisations (PHOs) on studies authorised during the reporting period. The performance of NSW PHOs on health and medical research are reported four times a year, each covering a 3-month period.

Overall Performance Environment

REGIS is the online platform used to manage ethics and governance applications for all NSW Public Health Organisations. OHMR has undertaken data validation activities with LHD Research Office staff to accurately represent research ethics and governance performance on this platform. These rolling validation activities may result in data reported here to differ from previous reports.

Update to Metrics Program

As reported previously, OHMR implemented the following changes to the Research Key Performance Indicators (KPIs) for inclusion in the Chief Executives' Services Agreement:

- Number of Greater than Low Risk projects (GLR) processed within application total time
 - 90 days for ethics, 60 days for governance
 - Threshold changes
 - >75% = Performing
 - 55%-75% = Underperforming
 - <55% = Not performing



Ethics Review Timelines of Human Research in NSW PHOs

KPI21-03: Ethics Application Approvals - By the Human Research Ethics Committee (HREC) within 90 calendar days

NSW State Benchmark: The benchmark for the 2021/22 financial year onwards is for reviewing human research studies by NSW PHO HRECs within 90 calendar days

Definition:

The proportion of Ethics applications (excluding LNR) approved by the HREC within 90 calendar days, approved within the reporting period.

Context:

The measure will no longer account for clock stops in accordance with the NHMRC Certification Handbook. Instead, the end-to-end time will be measured. Where a valid application is received, the clock starts on the submission closing date for the HREC meeting at which an application will be reviewed. The clock is stopped when the HREC formally notifies the applicant of the final decision.

Desired Outcome:

Ensuring timely processing of ethics approvals for research and clinical trials supports better health outcomes for the people of NSW and maintaining competitiveness through access to the latest treatments from clinical trials.

Selection Criteria Summary:

| | |
|-------------------|---|
| Scope | Human Research Ethics Applications |
| Frequency | Quarterly |
| Inclusions | <ul style="list-style-type: none"> Study Type = All Application Type = Greater than low risk Approval Type = Approved/ Approved with conditions within the reporting period |
| Exclusions | <ul style="list-style-type: none"> Application Type = Low and negligible risk Approval Type = Not within the reporting period Migrated studies |
| Total | Total time is defined as the measurement of the total, unadjusted time from the Submission Closing Date of the first meeting the application is assigned to, to when the final decision notification email is sent. |

Summary for Metric 3

Ethics review performance of NSW HRECs according to the < **90-day benchmark** for studies approved during the reporting period (**Quarter 1 2024**) are shown in **Table 1**.

During the reporting period, 209 studies (greater than low risk pathway) were approved by a NSW Health HREC with an average review time (total time) of 54 days. Of these 209 studies, 84 (40%) were classified as clinical trials (**Table 2**).

Further breakdown of clinical trial approvals by sponsor type is provided in **Table 3** (by NSW PHOs) and **Table 4** (by quarter). Historical performance of NSW PHOs against the old and new benchmarks for the review and approval of human research ethics applications is presented in **Table 5**.

Table 1. The **90 calendar days benchmark** for approval of human research ethics applications (**greater than low risk**) during the reporting period.

| NSW PHOs | Ethics Approval (Q1 2024) | | | | | |
|--------------|--|--------------------------------|---------------------------------|---------------------------|---|-------------------------|
| | All greater than low risk applications | | | | | |
| | Total Number of Applications | Total Time 90 Day Benchmark | | | Total Time Breakdown (calendar days) | |
| | | Count < 90 Day Benchmark | % < 90 Day Total Time Benchmark | Average Total Time (Days) | Average Research Office Time | Average Researcher Time |
| BLLBRRY | 29 | 26 | 90% | 50 | 26 | 23 |
| CINSW | 3 | 0 | 0% | 101 | 35 | 66 |
| HNELHD | 14 | 14 | 100% | 28 | 21 | 8 |
| ISLHD | 0 | 0 | - | - | - | - |
| JHFMHN | 3 | 3 | 100% | 75 | 0 | 75 |
| NBMLHD | 2 | 2 | 100% | 49 | 25 | 24 |
| NNSWLHD | 3 | 1 | 33% | 116 | 52 | 64 |
| NSLHD | 30 | 30 | 100% | 32 | 14 | 18 |
| SCHN | 12 | 9 | 75% | 60 | 26 | 34 |
| SESLHD | 15 | 10 | 67% | 81 | 53 | 28 |
| SLHD-CCD | 8 | 8 | 100% | 67 | 26 | 41 |
| SLHD-RPA | 26 | 26 | 100% | 54 | 31 | 23 |
| SVHN | 16 | 13 | 81% | 69 | 38 | 31 |
| SWSLHD | 15 | 8 | 53% | 111 | 75 | 36 |
| WNSWLHD | 9 | 6 | 67% | 74 | 35 | 39 |
| WSLHD | 24 | 13 | 54% | 85 | 41 | 45 |
| TOTAL | 209 | 169 | 81% | 54 | 33 | 20 |

Table 2. The 90 calendar days benchmark for the approval of clinical trials (greater than low risk) during the reporting period.

| NSW PHOs | Ethics Approval (Q1 2024) | | | | | |
|--------------|------------------------------|--------------------------------|------------------------------------|------------------------------|---|----------------------------|
| | Clinical Trials | | | | | |
| | Total Number of Applications | Total Time 90 Day Benchmark | | | Total Time Breakdown (calendar days) | |
| | | Count < 90 Day Benchmark | % < 90 Day Total Time Benchmark | Average Total Time (Days) | Average Research Office Time | Average Researcher Time |
| BLLBRRY | 29 | 25 | 86% | 50 | 26 | 23 |
| CINSW | 0 | 0 | - | - | - | - |
| HNELHD | 5 | 5 | 100% | 29 | 18 | 11 |
| ISLHD | 0 | 0 | - | - | - | - |
| JHFMHN | 0 | 0 | - | - | - | - |
| NBMLHD | 0 | 0 | - | - | - | - |
| NNSWLHD | 0 | 0 | - | - | - | - |
| NSLHD | 6 | 6 | 100% | 58 | 17 | 41 |
| SCHN | 5 | 5 | 100% | 39 | 17 | 23 |
| SESLHD | 7 | 6 | 86% | 56 | 45 | 11 |
| SLHD-CCD | 3 | 3 | 100% | 78 | 25 | 53 |
| SLHD-RPA | 11 | 11 | 100% | 59 | 39 | 20 |
| SVHN | 8 | 6 | 75% | 61 | 37 | 24 |
| SWSLHD | 4 | 0 | 0% | 168 | 108 | 59 |
| WNSWLHD | 0 | 0 | - | - | - | - |
| WSLHD | 6 | 2 | 33% | 91 | 38 | 53 |
| TOTAL | 84 | 63 | 75% | 61 | 34 | 27 |

Table 3. Breakdown of NSW PHO performances in **clinical trial approvals** (greater than low risk) during the reporting period **by sponsor type**

| | Collaborative group | | | Commercial entity | | | Investigator-initiated | | |
|--------------------|-------------------------|-------------------------------------|---------------------------|-------------------------|-------------------------------------|---------------------------|-------------------------|-------------------------------------|---------------------------|
| NSW PHOs | Total # of Applications | Average Research Office Time (days) | Average Total Time (days) | Total # of Applications | Average Research Office Time (days) | Average Total Time (days) | Total # of Applications | Average Research Office Time (days) | Average Total Time (days) |
| BLLBRRY | 0 | - | - | 27 | 26 | 50 | 2 | 27 | 43 |
| CINSW | 0 | - | - | 0 | - | - | 0 | - | - |
| HNELHD | 0 | - | - | 3 | 18 | 25 | 2 | 18 | 35 |
| ISLHD | 0 | - | - | 0 | - | - | 0 | - | - |
| JHFMHN | 0 | - | - | 0 | - | - | 0 | - | - |
| NBMLHD | 0 | - | - | 0 | - | - | 0 | - | - |
| NNSWLHD | 0 | - | - | 0 | - | - | 0 | - | - |
| NSLHD | 0 | - | - | 0 | - | - | 6 | 17 | 58 |
| SCHN | 0 | - | - | 4 | 14 | 39 | 1 | 30 | 42 |
| SESLHD | 1 | 44 | 53 | 1 | 74 | 41 | 5 | 40 | 60 |
| SLHD-CCD | 1 | 19 | 85 | 1 | 28 | 71 | 1 | 28 | 78 |
| SLHD-RPA | 5 | 36 | 56 | 1 | 26 | 57 | 5 | 44 | 62 |
| SVHN | 1 | 32 | 51 | 4 | 42 | 77 | 3 | 31 | 42 |
| SWSLHD | 1 | 161 | 194 | 2 | 97 | 191 | 1 | 78 | 95 |
| WNSWLHD | 0 | - | - | 0 | - | - | 0 | - | - |
| WSLHD | 1 | 38 | 106 | 3 | 52 | 96 | 2 | 17 | 75 |
| Grand Total | 10 | 48 | 77 | 46 | 32 | 59 | 28 | 31 | 57 |

Table 4. Quarterly **clinical trial approvals** (greater than low risk) in the last 3 reporting period (between 01/07/2023 and 31/03/2024), **by sponsor type**

| | Q3 2023 | | | Q4 2023 | | | Q1 2024 | | |
|------------------------|-------------------------|-------------------------------------|---------------------------|-------------------------|-------------------------------------|---------------------------|-------------------------|-------------------------------------|---------------------------|
| Sponsor Type | Total # of Applications | Average Research Office Time (days) | Average Total Time (days) | Total # of Applications | Average Research Office Time (days) | Average Total Time (days) | Total # of Applications | Average Research Office Time (days) | Average Total Time (days) |
| Collaborative Group | 18 | 31 | 51 | 15 | 24 | 41 | 10 | 48 | 77 |
| Commercial Entity | 48 | 30 | 49 | 44 | 34 | 55 | 46 | 32 | 59 |
| Investigator Initiated | 27 | 27 | 48 | 17 | 22 | 41 | 28 | 31 | 57 |
| Total | 93 | 29 | 49 | 76 | 26 | 43 | 84 | 26 | 43 |

Table 5. Historical performance of NSW PHOs against **the old and new benchmarks** for the review and approval of human research ethics applications (greater than low risk) in the last 3 reporting period (between 01/07/2023 and 31/03/2024).

| NSW PHOs | Q3 2023 | | | | | | | Q4 2023 | | | | | | | Q1 2024 | | | | | | |
|----------|------------------------------|-------------------------------|--------------------|-------------------------------------|----------------------------------|-------------------------------|---------------------------|------------------------------|-------------------------------|--------------------|-------------------------------------|----------------------------------|-------------------------------|---------------------------|------------------------------|-------------------------------|--------------------|-------------------------------------|----------------------------------|-------------------------------|---------------------------|
| | Total Number of Applications | 45 Day Benchmark (with clock) | | | 90 Day Benchmark (without clock) | | | Total Number of Applications | 45 Day Benchmark (with clock) | | | 90 Day Benchmark (without clock) | | | Total Number of Applications | 45 Day Benchmark (with clock) | | | 90 Day Benchmark (without clock) | | |
| | | Count 45 Day Benchmark | % 45 Day Benchmark | Average Research Office Time (Days) | Count 90 Day Benchmark | % 90 Day Total Time Benchmark | Average Total Time (Days) | | Count 45 Day Benchmark | % 45 Day Benchmark | Average Research Office Time (Days) | Count 90 Day Benchmark | % 90 Day Total Time Benchmark | Average Total Time (Days) | | Count 45 Day Benchmark | % 45 Day Benchmark | Average Research Office Time (Days) | Count 90 Day Benchmark | % 90 Day Total Time Benchmark | Average Total Time (Days) |
| | | | | | | | | | | | | | | | | | | | | | |
| BLLBRRY | 27 | 25 | 93% | 18 | 24 | 89% | 47 | 23 | 21 | 91% | 17 | 21 | 91% | 47 | 29 | 23 | 79% | 23 | 26 | 90% | 50 |
| CINSW | 5 | 5 | 100% | 15 | 5 | 100% | 49 | 5 | 4 | 80% | 34 | 4 | 80% | 74 | 3 | 1 | 33% | 66 | 0 | 0% | 101 |
| HNELHD | 22 | 21 | 95% | 14 | 22 | 100% | 30 | 32 | 32 | 100% | 7 | 32 | 100% | 23 | 14 | 14 | 100% | 8 | 14 | 100% | 28 |
| ISLHD | 5 | 5 | 100% | 18 | 5 | 100% | 54 | 0 | 0 | - | - | 0 | - | - | 0 | 0 | - | - | 0 | - | - |
| JHFMHN | 1 | 0 | 0% | 50 | 1 | 100% | 88 | 4 | 4 | 100% | 8 | 4 | 100% | 46 | 3 | 0 | 0% | 75 | 3 | 100% | 75 |
| NBMLHD | 3 | 3 | 100% | 23 | 1 | 33% | 93 | 3 | 3 | 100% | 16 | 3 | 100% | 45 | 2 | 1 | 50% | 24 | 2 | 100% | 49 |
| NNSWLHD | 2 | 2 | 100% | 7 | 2 | 100% | 48 | 1 | 1 | 100% | 38 | 1 | 100% | 70 | 3 | 2 | 67% | 64 | 1 | 33% | 116 |
| NSLHD | 31 | 31 | 100% | 14 | 31 | 100% | 40 | 39 | 38 | 97% | 15 | 39 | 100% | 34 | 30 | 27 | 90% | 18 | 30 | 100% | 32 |
| SCHN | 22 | 21 | 95% | 18 | 22 | 100% | 46 | 7 | 7 | 100% | 17 | 7 | 100% | 44 | 12 | 8 | 67% | 34 | 9 | 75% | 60 |
| SESLHD | 10 | 9 | 90% | 20 | 7 | 70% | 73 | 11 | 10 | 91% | 16 | 8 | 73% | 66 | 15 | 12 | 80% | 28 | 10 | 67% | 81 |
| SLHD-CCD | 6 | 5 | 83% | 29 | 6 | 100% | 52 | 14 | 10 | 71% | 32 | 14 | 100% | 54 | 8 | 4 | 50% | 41 | 8 | 100% | 67 |
| SLHD-RPA | 44 | 42 | 95% | 17 | 44 | 100% | 33 | 43 | 42 | 98% | 15 | 43 | 100% | 34 | 26 | 23 | 88% | 23 | 26 | 100% | 54 |
| SVHN | 16 | 12 | 75% | 29 | 13 | 81% | 55 | 31 | 20 | 65% | 47 | 22 | 71% | 78 | 16 | 12 | 75% | 31 | 13 | 81% | 69 |
| SWSLHD | 12 | 12 | 100% | 13 | 10 | 83% | 53 | 16 | 16 | 100% | 15 | 11 | 69% | 74 | 15 | 12 | 80% | 36 | 8 | 53% | 111 |
| WNSWLHD | 4 | 4 | 100% | 22 | 4 | 100% | 69 | 4 | 3 | 75% | 27 | 2 | 50% | 79 | 9 | 6 | 67% | 39 | 6 | 67% | 74 |
| WSLHD | 24 | 22 | 92% | 26 | 21 | 88% | 70 | 16 | 12 | 75% | 35 | 12 | 75% | 78 | 24 | 13 | 54% | 45 | 13 | 54% | 85 |
| TOTAL | 234 | 219 | 94% | 19 | 218 | 93% | 48 | 249 | 223 | 90% | 21 | 223 | 88% | 54 | 209 | 158 | 76% | 21 | 169 | 88% | 54 |



Site-specific Assessment (SSA) Authorisation Timelines of Human Research Projects in NSW PHOs

KPI21-04: Research Governance Application Authorisations – SSA Authorisations within 60 calendar days

NSW State Benchmark: The benchmark for the 2021/22 financial year onwards for authorisation of SSA applications is 60 calendar days

Definition:

The proportion of site-specific assessment (SSA) applications (excluding lower to negligible risk) authorised by the Research Governance Office (RGO) within 60 calendar days, authorised within the reporting period.

Context:

The measure will no longer account for clock stops in accordance with the National Health and Medical Research Council Certification. Handbook. Instead, the end-to-end time will be measured. The SSA application received date is the date the RGO or designee receives an SSA application from a researcher regardless of whether it is complete and/or deemed valid. The clock is stopped when the final SSA decision letter is provided to the site principal investigator.

Desired Outcome:

Ensuring timely processing of site approvals for research and clinical trials supports better health outcomes for the people of NSW and maintaining competitiveness through access to the latest treatments from clinical trials.

Selection Criteria Summary:

Scope

Site-specific assessment (SSA) applications

Frequency

Quarterly

Inclusions

- Study Type = All
- Application Type = Greater than low risk
- Approval Type = “Authorised” or “authorised with conditions” within the reporting period

Exclusions

- Application Type = Low and negligible risk
- Migrated studies

Total Time:

Total time is the measurement of the total, unadjusted time from the Submission Date to when the final decision notification email is sent granting approval.

Summary:

SSA review performance of NSW PHOs according to the **<60-day benchmark** for studies authorised during the reporting period (**Quarter 1 2024**) are shown in **Table 6**. During the reporting period,

376 studies (greater than low risk pathway) were authorised in NSW PHOs with an average review time (total time) of **51** days.

Of these **376** studies, **194** were classified as clinical trials (**Table 7**).

Further breakdown of clinical trial SSA authorisations by sponsor type is provided in **Table 8** (by NSW PHOs) and **Table 9** (by quarter). Historical performance of NSW PHOs against the old and new benchmarks for the review and authorisation of governance applications is presented in **Table 10**.

Table 6: The 60 calendar days benchmark for authorisation of governance applications (greater than low risk) during the reporting period.

| NSW PHOs | SSA Approvals (Q1 2024) | | | | | | | |
|--------------|--|----------------------------------|---------------------------------|---------------------------|--------------------------------------|---------------------------|-------------------------|-------------------------|
| | All greater than low risk applications | | | | | | | |
| | | 60 Day Benchmark (without clock) | | | Total Time Breakdown (calendar days) | | | |
| | Total Number of Applications | Count of < 60 Day Benchmark | % < 60 Day Total Time Benchmark | Average Total Time (Days) | Average Research Office Time | Average Head of Dept Time | Average Chief Exec Time | Average Researcher Time |
| ASNSW | 1 | 1 | 100% | 18 | 14 | 4 | 0 | 0 |
| Calvary | 9 | 9 | 100% | 12 | 10 | 2 | 1 | 0 |
| CCLHD | 7 | 7 | 100% | 33 | 9 | 8 | 0 | 16 |
| FWLHD | 0 | 0 | - | - | - | - | - | - |
| HNELHD | 22 | 20 | 91% | 25 | 10 | 5 | 2 | 11 |
| ISLHD | 4 | 4 | 100% | 8 | 3 | 5 | 2 | 0 |
| JHFMHN | 0 | 0 | - | - | - | - | - | - |
| MLHD | 2 | 2 | 100% | 21 | 11 | 4 | 1 | 7 |
| MNCLHD | 9 | 9 | 100% | 30 | 9 | 5 | 9 | 16 |
| NBMLHD | 6 | 4 | 67% | 77 | 28 | 46 | 3 | 3 |
| NNSWLHD | 2 | 2 | 100% | 57 | 14 | 1 | 4 | 43 |
| NSLHD | 48 | 46 | 96% | 39 | 18 | 7 | 4 | 13 |
| NSWHPTH | 7 | 0 | 0% | 132 | 40 | 36 | 1 | 55 |
| SCHN | 6 | 3 | 50% | 67 | 21 | 17 | 1 | 29 |
| SESLHD | 43 | 38 | 88% | 42 | 9 | 12 | 0 | 20 |
| SLHD-CCD | 18 | 18 | 100% | 26 | 9 | 7 | 12 | 4 |
| SLHD-RPA | 50 | 49 | 98% | 32 | 13 | 7 | 9 | 11 |
| SNSWLHD | 2 | 0 | 0% | 165 | 165 | 0 | 0 | 0 |
| SVHN | 22 | 16 | 73% | 54 | 11 | 9 | 1 | 33 |
| SWSLHD | 48 | 9 | 19% | 102 | 55 | 14 | 1 | 33 |
| WNSWLHD | 5 | 3 | 60% | 48 | 9 | 18 | 0 | 21 |
| WSLHD | 65 | 45 | 69% | 50 | 12 | 10 | 5 | 28 |
| TOTAL | 376 | 286 | 76% | 51 | 20 | 10 | 4 | 21 |

Table 7: The 60 calendar days benchmark for the authorisation of clinical trials (greater than low risk) during the reporting period.

| NSW PHOs | SSA Approvals (Q1 2024) Clinical Trials | | | | | | | |
|--------------|--|----------------------------------|---------------------------------|---------------------------|--------------------------------------|---------------------------|-------------------------|-------------------------|
| | Total Number of Applications | 60 Day Benchmark (without clock) | | | Total Time Breakdown (calendar days) | | | |
| | | Count of < 60 Day Benchmark | % < 60 Day Total Time Benchmark | Average Total Time (Days) | Average Research Office Time | Average Head of Dept Time | Average Chief Exec Time | Average Researcher Time |
| ASNSW | 0 | 0 | - | - | - | - | - | - |
| CALVARY | 7 | 7 | 100% | 12 | 10 | 2 | 1 | 0 |
| CCLHD | 4 | 4 | 100% | 26 | 11 | 5 | 0 | 10 |
| FWLHD | 0 | 0 | - | - | - | - | - | - |
| HNELHD | 6 | 5 | 83% | 20 | 7 | 6 | 3 | 7 |
| ISLHD | 2 | 2 | 100% | 4 | 2 | 2 | 2 | 0 |
| JHFMHN | 0 | 0 | - | - | - | - | - | - |
| MLHD | 0 | 0 | - | - | - | - | - | - |
| MNCLHD | 6 | 6 | 100% | 34 | 13 | 8 | 12 | 12 |
| NBMLHD | 2 | 1 | 50% | 73 | 6 | 62 | 2 | 5 |
| NNSWLHD | 1 | 1 | 100% | 56 | 27 | 1 | 7 | 28 |
| NSLHD | 22 | 21 | 95% | 40 | 21 | 8 | 4 | 11 |
| NSWHPH | 1 | 0 | 0 | 70 | 13 | 21 | 3 | 36 |
| SCHN | 2 | 0 | 0% | 87 | 17 | 9 | 1 | 62 |
| SESLHD | 22 | 21 | 95% | 41 | 11 | 16 | 0 | 14 |
| SLHD-CCD | 11 | 11 | 100% | 33 | 13 | 9 | 15 | 5 |
| SLHD-RPA | 29 | 28 | 97% | 35 | 15 | 6 | 12 | 13 |
| SNSWLHD | 1 | 0 | 0% | 105 | 105 | 0 | 0 | 0 |
| SVHN | 13 | 10 | 77% | 51 | 11 | 9 | 1 | 31 |
| SWSLHD | 28 | 5 | 18% | 104 | 57 | 20 | 1 | 26 |
| WNSWLHD | 3 | 1 | 33% | 50 | 13 | 23 | 0 | 14 |
| WSLHD | 34 | 24 | 71% | 43 | 13 | 11 | 5 | 18 |
| TOTAL | 194 | 147 | 76% | 51 | 22 | 12 | 5 | 17 |

Table 9. Quarterly clinical trial authorisations (greater than low risk applications) approved during the last 3 reporting period, by sponsor type

| | Q3 2023 | | | Q4 2023 | | | Q1 2024 | | |
|------------------------|-------------------------|-------------------------|--------------------|-------------------------|-------------------------|--------------------|-------------------------|-------------------------|--------------------|
| Sponsor Type | Total # of Applications | Average Research Office | Average Total Time | Total # of Applications | Average Research Office | Average Total Time | Total # of Applications | Average Research Office | Average Total Time |
| Collaborative Group | 50 | 12 | 43 | 69 | 24 | 51 | 48 | 28 | 63 |
| Commercial Entity | 118 | 9 | 28 | 140 | 17 | 35 | 105 | 20 | 42 |
| Investigator Initiated | 60 | 19 | 44 | 59 | 15 | 53 | 40 | 20 | 60 |
| Total | 228 | 12 | 35 | 268 | 18 | 47 | 193 | 22 | 47 |

Table 10. Historical performance of NSW PHOs against the old and new benchmarks for the review and authorisation of SSA applications (greater than low risk) for the last 3 reporting periods (between 01/07/2023 and 31/03/2024).

| | Q3 2023 | | | | | | | Q4 2023 | | | | | | | Q1 2024 | | | | | | |
|--------------|------------------------|-------------------------------|--------------------|------------------------|----------------------------------|-------------------------------|---------------------------|------------------------|----------------------------------|--------------------|------------------------|----------------------------------|-------------------------------|---------------------------|------------------------|-------------------------------|--------------------|------------------------|----------------------------------|-------------------------------|---------------------------|
| LHD | Number of Applications | 15 Day Benchmark (with clock) | | | 60 Day Benchmark (without clock) | | | Number of Applications | 15 Day Benchmark (without clock) | | | 60 Day Benchmark (without clock) | | | Number of Applications | 15 Day Benchmark (with clock) | | | 60 Day Benchmark (without clock) | | |
| | | Count of 15 Day Benchmark | % 15 Day Benchmark | Average RO Time (Days) | Count of 60 Day Benchmark | % 60 Day Total Time Benchmark | Average Total Time (Days) | | Count of 15 Day Benchmark | % 15 Day Benchmark | Average RO Time (Days) | Count of 60 Day Benchmark | % 60 Day Total Time Benchmark | Average Total Time (Days) | | Count of 15 Day Benchmark | % 15 Day Benchmark | Average RO Time (Days) | Count of 60 Day Benchmark | % 60 Day Total Time Benchmark | Average Total Time (Days) |
| ASNSW | 3 | 1 | 0.3333 | 64 | 1 | 33% | 158 | 0 | 0 | - | - | 0 | - | - | 1 | 1 | 1 | 14 | 1 | 100% | 18 |
| CALVARY | 7 | 6 | 86% | 8 | 7 | 100% | 11 | 12 | 9 | 75% | 9 | 12 | 100% | 11 | 9 | 8 | 89% | 10 | 9 | 100% | 12 |
| CCLHD | 11 | 10 | 91% | 5 | 11 | 100% | 13 | 11 | 9 | 82% | 9 | 10 | 91% | 28 | 7 | 6 | 86% | 9 | 7 | 100% | 33 |
| FWLHD | 1 | 1 | 100% | 11 | 1 | 100% | 11 | 0 | 0 | - | - | 0 | - | - | 0 | 0 | - | - | 0 | - | - |
| HNELHD | 33 | 21 | 64% | 13 | 33 | 100% | 27 | 50 | 27 | 54% | 14 | 49 | 98% | 30 | 22 | 18 | 82% | 10 | 20 | 91% | 25 |
| ISLHD | 17 | 17 | 100% | 2 | 17 | 100% | 5 | 19 | 19 | 100% | 1 | 18 | 95% | 8 | 4 | 4 | 100% | 3 | 4 | 100% | 8 |
| JHFMHN | 2 | 0 | 0% | 46 | 2 | 100% | 51 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | 0 | - | - | 0 | - | - |
| MLHD | 4 | 3 | 75% | 11 | 4 | 100% | 18 | 10 | 9 | 90% | 6 | 10 | 100% | 32 | 2 | 2 | 100% | 11 | 2 | 100% | 21 |
| MNCLHD | 6 | 6 | 100% | 6 | 6 | 100% | 19 | 8 | 7 | 88% | 7 | 7 | 88% | 27 | 9 | 6 | 67% | 9 | 9 | 100% | 30 |
| NBMLHD | 7 | 1 | 14% | 36 | 7 | 100% | 53 | 20 | 7 | 35% | 32 | 17 | 85% | 58 | 6 | 2 | 33% | 28 | 4 | 67% | 77 |
| NNSWLHD | 9 | 6 | 67% | 13 | 9 | 100% | 22 | 4 | 3 | 75% | 5 | 4 | 100% | 39 | 2 | 1 | 50% | 14 | 2 | 100% | 57 |
| NSLHD | 47 | 27 | 57% | 14 | 44 | 94% | 30 | 60 | 36 | 60% | 14 | 53 | 88% | 38 | 48 | 26 | 54% | 18 | 46 | 96% | 39 |
| NSWHPH | 12 | 1 | 8% | 35 | 10 | 83% | 61 | 2 | 0 | 0% | 28 | 1 | 50% | 74 | 7 | 2 | 29% | 40 | 0 | 0% | 132 |
| SCHN | 21 | 17 | 81% | 9 | 21 | 100% | 34 | 58 | 47 | 81% | 9 | 52 | 90% | 35 | 6 | 2 | 33% | 21 | 3 | 50% | 67 |
| SESLHD | 38 | 22 | 58% | 13 | 26 | 68% | 49 | 52 | 34 | 65% | 14 | 41 | 79% | 48 | 43 | 36 | 84% | 9 | 38 | 88% | 42 |
| SLHD-CCD | 16 | 14 | 88% | 5 | 16 | 100% | 25 | 29 | 23 | 79% | 8 | 29 | 100% | 25 | 18 | 12 | 67% | 9 | 18 | 100% | 26 |
| SLHD-RPA | 60 | 51 | 85% | 6 | 60 | 100% | 24 | 93 | 75 | 81% | 8 | 90 | 97% | 26 | 50 | 33 | 66% | 13 | 49 | 98% | 32 |
| SNSWLHD | 0 | 0 | - | - | 0 | - | - | 2 | 1 | 50% | 38 | 1 | 50% | 46 | 2 | 0 | 0% | 165 | 0 | 0% | 165 |
| SVHN | 41 | 32 | 78% | 19 | 28 | 68% | 60 | 34 | 25 | 74% | 10 | 23 | 68% | 54 | 22 | 18 | 82% | 11 | 16 | 73% | 54 |
| SWSLHD | 47 | 8 | 17% | 28 | 39 | 83% | 50 | 43 | 6 | 14% | 54 | 14 | 33% | 92 | 48 | 4 | 8% | 55 | 9 | 19% | 102 |
| WNSWLHD | 8 | 8 | 100% | 5 | 8 | 100% | 11 | 8 | 5 | 63% | 13 | 7 | 88% | 22 | 5 | 4 | 80% | 9 | 3 | 60% | 48 |
| WSLHD | 71 | 63 | 89% | 9 | 63 | 89% | 34 | 77 | 65 | 84% | 9 | 63 | 82% | 40 | 65 | 48 | 74% | 12 | 45 | 69% | 50 |
| Total | 461 | 315 | 68% | 14 | 413 | 90% | 36 | 592 | 407 | 69% | 14 | 508 | 86% | 40 | 376 | 233 | 62% | 20 | 286 | 76% | 51 |

A list of NSW PHOs names and abbreviations that review and/or authorise human research studies:

| Human Research Ethics Committee/ Research Governance Office Names | Abbreviation used in the tables | Ethics | Site |
|---|------------------------------------|--------|------|
| Ambulance Service of NSW | ASNSW | | Yes |
| Bellberry | BLLBRRY | Yes | |
| Calvary Mater Hospital Newcastle | CALVARY | | Yes |
| Central Coast LHD | CCLHD | | Yes |
| NSW Population & Health Services Research Ethics Committee | CINSW | Yes | |
| Greater Western LHD | WNSWLHD | Yes | Yes |
| Hammond Care | HCARE | | Yes |
| Hunter New England LHD | HNELHD | Yes | Yes |
| Justice Health & Forensic Mental Health Network | JHFMHN | Yes | Yes |
| Mid North Coast LHD | MNCLHD | | Yes |
| Murrumbidgee LHD | MLHD | | Yes |
| Northern NSW LHD | NNSWLHD | Yes | Yes |
| Nepean Blue Mountains LHD | NBMLHD | Yes | Yes |
| Northern Sydney LHD | NSLHD | Yes | Yes |
| NSW Health Pathology | NSWHPTH | | Yes |
| Royal Rehabilitation Centre Sydney HREC | RRCS | Yes | |
| Sydney Children's Hospitals Network | SCHN | Yes | Yes |
| South Eastern Sydney LHD | SESLHD | Yes | Yes |
| Sydney LHD (Concord Zone) | SLHD – CCD | Yes | Yes |
| Sydney LHD (RPAH Zone) | SLHD – RPA | Yes | Yes |
| Southern NSW LHD | SNSWLHD | | Yes |
| St Vincent's Hospital | SVHN | Yes | Yes |
| South Western Sydney LHD | SWSLHD | Yes | Yes |
| Illawarra Shoalhaven LHD (joint committee with University of Wollongong) | ISLHD | Yes | Yes |
| Western Sydney LHD | WSLHD | Yes | Yes |



For more information

This report has been prepared by the Research Ethics and Governance Unit in Office for Health and Medical Research.

For further enquiries and for the use of this report please contact:

James Cokayne

Principal Policy Officer

Research Ethics and Governance Unit

Office for Health and Medical Research

[Tel \(02\) 9391 9920](tel:(02)93919920) | james.cokayne@health.nsw.gov.au

Ambika MV Murthy

Senior Policy Officer

Research Ethics and Governance Unit

Office for Health and Medical Research

[Tel \(02\)9269 5558](tel:(02)92695558) | Ambika.Murthy@health.nsw.gov.au

Deb Aldridge

Policy Officer and Data Analyst

Research Ethics and Governance Unit

Office for Health and Medical Research

[Tel \(02\) 9461 7462](tel:(02)94617462) | deborah.aldridge@health.nsw.gov.au